NEXTECH VI ONCOLOGY SCSP 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:35 pm Unchanged |
2022-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
NEXTECH VI ONCOLOGY SCSP | 1,910,029 2.000% |
0 (Unchanged) |
Filing |
| 2021-02-16 4:01 pm Purchase |
2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
NEXTECH VI ONCOLOGY SCSP | 1,910,029 5.500% |
1,910,029 (New Position) |
Filing |